Tangen Biosciences has been awarded a contract to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and is emerging as a public health threat
Tangen has developed a molecular diagnostic platform called TangenDxTM – a small footprint, rapid, highly sensitive, and low-cost system.